Rogier Rooswinkel

Rogier Rooswinkel is Partner at Forbion where he is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. He currently serves as a board member of Achilles and as a board observer for Enterprise, Prilenia and Escalier. Prior to joining Forbion, Rogier worked as a post-doc in immunology at the Netherlands Cancer Institute. Rogier holds a PhD from the University of Amsterdam and a master’s degree in Oncology from the VU University of Amsterdam.